ACTRN12619000963123招募中4 期
Effect of Aflibercept on best corrected visual acuity in patients with Diabetic Macular Oedema: Outcomes Using a Treat and Extend Protocol
The Royal Adelaide Hospital0 个研究点目标入组 50 人开始时间: 2019年7月8日最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •1. Adult patients 18 years or over with a diagnosis of type 1 or 2 diabetes mellitus.
- •2. Treatment naïve eyes with evidence of centre involving DMO on FFA and OCT.
- •3. BCVA equal to between 73 (6/9.5) and 24 (6/95) ETDRS letters inclusive.
- •4. Definite retinal thickening on clinical examination due to DMO involving the central macula.
- •5. Media clarity, pupillary dilatation and individual cooperation to allow adequate fundus photographs.
- •6. Central subfield thickness on Heidelberg Spectralis of equal to or greater than 300um.
排除标准
- •1. Previous treatment with an anti-VEGF agent or intravitreal triamcinolone acetate.
- •2. Active proliferative diabetic retinopathy in the study eye.
- •3. Neovascularisation of the iris or angle.
- •4. Previous macular laser or pan retinal photocoagulation treatment within the last 4 months.
- •5. Maculopathy due to another cause.
- •6. History of retinal detachment or surgery for retinal detachment.
- •7. Previous vitrectomy.
- •8. Any existing ocular disorder that would prevent improvement in visual acuity such as macular ischaemia, dense foveal lipid exudates, epiretinal membrane or macular hole, or any significant media opacities such as cataract, which, in an otherwise healthy eye would reduce the vision to less than 6/12.
- •9. Aphakia
- •10. YAG laser use in the 2 months prior to treatment.
- •11. Any active periocular or intraocular infection or severe blepharitis.
- •12. Any active intraocular inflammation or uncontrolled intraocular pressure.
- •13. Any known hypersensitivity to aflibercept or any of the excipients in aflibercept.
- •14. Any arterial thromboembolic event including stoke, myocardial infarction or vascular embolism in the last 3 months.
- •15. Any positive pregnancy or current breast feeding or patients who are planning for a pregnancy or likely to be breast feeding over the next 24 months.
- •16. Chronic renal failure requiring dialysis or transplant.
- •17. Unstable blood pressure >180/110, cardiovascular disease or glycaemic control (BSL more often than not over 20mmol/L).
- •18. Participation within another trial of an unapproved drug within 30 days of entry into this trial.
- •19. Myocardial infarct, other acute cardiovascular event requiring hospitalisation, stroke, transient ischaemic attack, or treatment for acute congestive heart failure within 4 months prior to entry into the study.
- •20. Systemic anti-VEGF or pro-VEGF treatment within four months prior to study entry or anticipated use of the drug during the study period.
研究者
相似试验
已完成
4 期
Visual functions in patients with diabetic macular edema following aflibercept therapy.JPRN-jRCTs031180161Okamoto Fumiki20
进行中（未招募）
1 期
The Effect of Intravitreal Aflibercept on Ocular Perfusion – a Pilot StudyExudative AMDMedDRA version: 19.1Level: LLTClassification code 10025411Term: Macular degeneration senileSystem Organ Class: 100000004853EUCTR2016-004608-78-ATKepler University Hospital, Institute of Ophthalmology
进行中（未招募）
1 期
Antibody treatment in retinal vein occulsion and the influence on oxygen and blood supplyretinal vein occlusionEUCTR2016-001660-10-ATniversitätsklinik für Augenheilkunde und Optometrie30
招募中
2 期
Role of Dalfampridine in optic neuritisCTRI/2021/07/034725Department of Health Research
已完成
不适用
Efficacy of Aflibercept for macular edema in our hospitaldiabetic macular edema, retinal vein occlusionJPRN-UMIN000048108Chiba University300